Lee Rose
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Honeywell Q3 Earnings Expected to Decline. Honeywell’s upcoming third‑quarter earnings are projected to fall short of previous results. Analysts point out that the company’s long‑term outlook still looks appealing. A recent comparison article suggests Honeywell may be a stronger choice than Corning for 2026.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Crown Holdings Price Target to $116. UBS has lowered its price target for Crown Holdings to $116 while maintaining a Neutral rating. This new target is below the current support level of $118.66, suggesting potential downside pressure. The move stands out as the new target is significantly lower than the average analyst estimate of $136.57.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DuPont receives analyst upgrades and announces quarterly dividend. DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.
Transaction History
| SOLS | ▲ Buy | Option Exercise | 1,785 | — | 5/22/2026 | View on chart |
| SOLS | ▲ Buy | Option Exercise | 2,476 | — | 4/15/2026 | View on chart |
| HON | ▲ Buy | Option Exercise | 650 | $130K | 4/15/2025 | View on chart |
| HON | ▲ Buy | Option Exercise | 335 | $66K | 4/15/2024 | View on chart |
| HON | ▲ Buy | Option Exercise | 349 | $69K | 4/15/2023 | View on chart |
| HON | ▲ Buy | Option Exercise | 88 | $17K | 4/15/2022 | View on chart |
| CCK | ▲ Buy | Grant | 336 | $40K | 2/17/2022 | View on chart |
| CCK | ▲ Buy | Grant | 348 | $36K | 11/3/2021 | View on chart |
| DD | ▼ Sell | Open Market | 13,251 | $986K | 8/24/2021 | View on chart |
| DD | ▲ Buy | Option Exercise | 13,197 | $706K | 8/24/2021 | View on chart |
| DD | ▼ Sell | Open Market | 13,197 | $982K | 8/24/2021 | View on chart |
| DD | ▲ Buy | Option Exercise | 13,251 | $877K | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solstice Settles Lawsuit; Mizuho Cuts Target to $65
Solstice Advanced Materials announced a settlement with plaintiffs, stating it does not expect a material impact on business operations or financial performance. In related analyst activity, Mizuho lowered its price target to $65 while maintaining a Neutral rating, whereas RBC Capital reiterated an Outperform rating with an $82 target. The company is also scheduled to report third-quarter results on November 4, 2026.
Solstice Settles Lawsuit; Mizuho Cuts Target to $65. Solstice Advanced Materials announced a settlement with plaintiffs, stating it does not expect a material impact on business operations or financial performance. In related analyst activity, Mizuho lowered its price target to $65 while maintaining a Neutral rating, whereas RBC Capital reiterated an Outperform rating with an $82 target. The company is also scheduled to report third-quarter results on November 4, 2026.